Cargando…

A phase II trial of BAY 43-9006 (sorafenib) (NSC-724772) in patients with relapsing and resistant multiple myeloma: SWOG S0434

The authors assessed the overall response rate, including confirmed complete response (CR) and partial response, in patients with relapsed/refractory multiple myeloma treated with sorafenib. Qualitative and quantitative toxicities associated with this regimen were evaluated. Patients were eligible i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Srkalovic, Gordan, Hussein, Mohamad A, Hoering, Antje, Zonder, Jeffrey A, Popplewell, Leslie L, Trivedi, Harsha, Mazzoni, Sandy, Sexton, Rachel, Orlowski, Robert Z, Barlogie, Bart
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2014
Materias:	Clinical Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4302677/ https://www.ncbi.nlm.nih.gov/pubmed/24913924 http://dx.doi.org/10.1002/cam4.276

Ejemplares similares

A Phase Ib Study of Sorafenib (BAY 43‐9006) in Patients with Kaposi Sarcoma
por: Uldrick, Thomas S., et al.
Publicado: (2017)

Phase I safety data of lenalidomide, bortezomib, dexamethasone, and elotuzumab as induction therapy for newly diagnosed symptomatic multiple myeloma: SWOG S1211
por: Usmani, S Z, et al.
Publicado: (2015)

A phase II study of sorafenib (BAY 43–9006) in recurrent diffuse large B cell lymphoma: an eastern cooperative oncology group study (E1404)
por: Greenwald, Daniel R, et al.
Publicado: (2013)

P965: FOLLOW-UP ANALYSIS OF THE RANDOMIZED PHASE II TRIAL OF BORTEZOMIB, LENALIDOMIDE, DEXAMTHASONE WITH/WITHOUT ELOTUZUMAB FOR NEWLY DIAGNOSED, HIGH RISK MULTIPLE MYELOMA (SWOG-1211)
por: Usmani, S., et al.
Publicado: (2022)

Synergistic inhibition of human melanoma proliferation by combination treatment with B-Raf inhibitor BAY43-9006 and mTOR inhibitor Rapamycin
por: Molhoek, Kerrington R, et al.
Publicado: (2005)

Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours
por: Awada, A, et al.
Publicado: (2005)

P04.34. Should Medicare expand allowable chiropractic services?
por: Whedon, J
Publicado: (2012)

Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT)
por: Durie, Brian G. M., et al.
Publicado: (2020)

Flow cytometry defined cytoplasmic immunoglobulin index is a major prognostic factor for progression of asymptomatic monoclonal gammopathies to multiple myeloma (subset analysis of SWOG S0120)
por: Papanikolaou, X, et al.
Publicado: (2016)

S0941: a phase 2 SWOG study of sorafenib and erlotinib in patients with advanced gallbladder carcinoma or cholangiocarcinoma
por: El-Khoueiry, A B, et al.
Publicado: (2014)

Phase II Trial of Sorafenib in Combination with Carboplatin and Paclitaxel in Patients with Metastatic Uveal Melanoma: SWOG S0512
por: Bhatia, Shailender, et al.
Publicado: (2012)

0434. Simulation of late inspiratory rise in airway pressure during pressure support ventilation
por: Yu, C-H, et al.
Publicado: (2014)

Disease and outcome disparities in multiple myeloma: exploring the role of race/ethnicity in the Cooperative Group clinical trials
por: Ailawadhi, Sikander, et al.
Publicado: (2018)

Compound F779-0434 causes synthetic lethality in BRCA2-deficient cancer cells by disrupting RAD52–ssDNA association
por: Li, Jian, et al.
Publicado: (2018)

NSC-derived exosomes enhance therapeutic effects of NSC transplantation on cerebral ischemia in mice
por: Zhang, Ruolin, et al.
Publicado: (2023)

Drug-drug interactions in subjects enrolled in SWOG trials of oral chemotherapy
por: Marcath, Lauren A., et al.
Publicado: (2021)

Higher capecitabine AUC in elderly patients with advanced colorectal cancer (SWOGS0030)
por: Louie, S G, et al.
Publicado: (2013)

Endothelial cell secreted VEGF-C enhances NSC VEGFR3 expression and promotes NSC survival
por: Matta, Rita, et al.
Publicado: (2021)

P.0434 Pre-existing vitamin D supplementation as a protective factor in COVID-19 infection in elderly schizophrenia and dementia inpatients: a case series
por: Shelef, A., et al.
Publicado: (2021)

NSC800 microprocessor family handbook.
Publicado: (1981)

Letter to the Member of the NSC and others concerned on the fusion of the NSC with Emulsion Experiments Committee into the new Physics III Committee
por: Ericson, T
Publicado: (1966)

Characteristics and prognostic impact of IDH mutations in AML: a COG, SWOG, and ECOG analysis
por: Zarnegar-Lumley, Sara, et al.
Publicado: (2023)

Pre-treatment Amino Acids and Risk of Paclitaxel-induced Peripheral Neuropathy in SWOG S0221
por: Chen, Ciao-Sin, et al.
Publicado: (2023)

ARC (NSC 188491) has identical activity to Sangivamycin (NSC 65346) including inhibition of both P-TEFb and PKC
por: Stockwin, Luke H, et al.
Publicado: (2009)

Agenda for the meeting of the NSC on 11 January 1965
por: Ericson, T
Publicado: (1965)

Agenda for the NSC meeting on 12 February 1965
por: Ericson, T
Publicado: (1965)

Agenda for the NSC meeting on 12 March 1965
por: Ericson, T
Publicado: (1965)

Agenda for the NSC meeting on 15 November 1965
por: CERN. Geneva. Nuclear Structure Committee
Publicado: (1965)

Agenda for the NSC meeting on 13 June 1966
por: Ericson, T
Publicado: (1965)

Third Conference on nonlinear science and complexity (NSC)
por: Luo, Albert, et al.
Publicado: (2012)

Activity of GR30921X (NSC 382057) and GR63178A (NSC D611615) in human ovarian cancer lines.
por: Boven, E., et al.
Publicado: (1990)

Body Mass Index and Weight Loss in Metastatic Colorectal Cancer in CALGB (Alliance)/SWOG 80405
por: Guercio, Brendan J, et al.
Publicado: (2020)

An evaluation of stakeholder engagement in comparative effectiveness research: lessons learned from SWOG S1415CD
por: Bell-Brown, Ari, et al.
Publicado: (2022)

Immune profiling of pre- and post-treatment breast cancer tissues from the SWOG S0800 neoadjuvant trial
por: Li, Xiaotong, et al.
Publicado: (2019)

Antiviral therapy use and related outcomes in patients with cancer and viral infections: results from SWOG S1204
por: Hwang, Jessica P., et al.
Publicado: (2022)

Evaluation of the Sensitivity to Endocrine Therapy Index and 21-Gene Breast Recurrence Score in the SWOG S8814 Trial
por: Speers, Corey W., et al.
Publicado: (2023)

Prevention of multidrug resistance (MDR) in osteosarcoma by NSC23925
por: Yang, X, et al.
Publicado: (2014)

NSC348884 cytotoxicity is not mediated by inhibition of nucleophosmin oligomerization
por: Šašinková, Markéta, et al.
Publicado: (2021)

WRN-targeted therapy using inhibitors NSC 19630 and NSC 617145 induce apoptosis in HTLV-1-transformed adult T-cell leukemia cells
por: Moles, R., et al.
Publicado: (2016)

Incidence and risk factors of venous thromboembolism (VTD) in patients with amyloidosis
por: Srkalovic, Gordan, et al.
Publicado: (2005)

Cannot write session to /tmp/vufind_sessions/sess_u2vpfqiohpg9q74qnmurgio944